×
About 2,868 results

ALLMedicine™ Hypophosphatemia Center

Research & Reviews  877 results

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
https://clinicaltrials.gov/ct2/show/NCT03478839

Jun 24th, 2022 - This is a natural history study of patients with Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). GACI is an ultra-rare disorder with an estimated birth prevalence of around 1 in ...

Genetic and clinical profile of patients with hypophosphatemic rickets.
https://doi.org/10.1016/j.ejmg.2022.104540
European Journal of Medical Genetics; Marik B, Bagga A et. al.

Jun 24th, 2022 - Nutritional vitamin D deficiency is the most frequent cause of rickets followed by genetic causes, that include entities classic hypophosphatemic rickets (FGF23 related), Dent disease, Fanconi syndrome, renal tubular acidosis, and vitamin D depend...

Higher parenteral electrolyte intakes in preterm infants during first week of life: Eff...
https://doi.org/10.1097/MPG.0000000000003532
Journal of Pediatric Gastroenterology and Nutrition; Späth C, Sjöström ES et. al.

Jun 22nd, 2022 - This study aimed to investigate the effects of a higher intake of electrolytes from parenteral nutrition (PN) on plasma electrolyte concentrations in very low birth weight (VLBW, <1500 g) infants. This was a single-centre cohort study including al...

Osmotic demyelination syndrome: novel risk factors and proposed pathophysiology.
https://doi.org/10.1111/imj.15855
Internal Medicine Journal; Ambati R, Kho LK et. al.

Jun 20th, 2022 - Osmotic demyelination syndrome (ODS) is non inflammatory demyelination in response to an osmotic challenge. It can be pontine or extrapontine in presentation AIM: Retrospective review of cases involving ODS and define the spectrum of causes, risk ...

see more →

Drugs  94 results see all →

Clinicaltrials.gov  71 results

Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)
https://clinicaltrials.gov/ct2/show/NCT03478839

Jun 24th, 2022 - This is a natural history study of patients with Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2). GACI is an ultra-rare disorder with an estimated birth prevalence of around 1 in ...

Examining the Effect of Burosumab on Muscle Function
https://clinicaltrials.gov/ct2/show/NCT04146935

Jun 10th, 2022 - X-linked hypophosphatemia is a skeletal dysplasia. The mineralized tissue complications of XLH have been the focus of investigative studies seeking to understand its pathogenesis, as well as studies directed at new therapies. However, in addition ...

X-linked Hypophosphatemia Disease Monitoring Program
https://clinicaltrials.gov/ct2/show/NCT03651505

Jun 2nd, 2022 - The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of burosu...

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
https://clinicaltrials.gov/ct2/show/NCT03920072

May 20th, 2022 - XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. XLH is the most common inherited form of rickets and the most common inherited defect in renal tubular phosphate transport. XLH is tran...

The Impact of Phosphate Metabolism on Healthy Aging
https://clinicaltrials.gov/ct2/show/NCT03771105

May 18th, 2022 - The central hypothesis of this proposal is that patients with X-linked hypophosphatemia (XLH), when matched for duration and dose of phosphate (Pi) therapy to patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH), will evide...

see more →

News  105 results

X-Linked Hypophosphatemia Exacts Early, High Toll on Musculoskeletal System
https://www.medscape.com/viewarticle/962020

Nov 2nd, 2021 - NEW YORK (Reuters Health) - Adults with X-linked hypophosphatemia (XLH) have high rates of musculoskeletal problems that start as early as age 20 years and gradually accumulate over the years, a new analysis confirms. XLH is a rare inherited disor...

Dr. Sonpavde on the Safety Profile of Erdafitinib in Bladder Cancer
https://www.onclive.com/view/dr-sonpavde-on-the-safety-profile-of-erdafitinib-in-bladder-cancer

Oct 6th, 2021 - Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the safety profile of erdafitinib (Balversa), which was approved by the FDA in April 2019 to treat adult patients with locally advanced or metas...

HR-positive breast cancer: Entinostat fails phase 3 trial
https://www.mdedge.com/hematology-oncology/article/245091/breast-cancer/hr-positive-breast-cancer-entinostat-fails-phase-3

Aug 31st, 2021 - Key clinical point: Adding entinostat to e xemestane does not improve survival in aromatase inhibitor (AI)-resistant advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Major finding: Th.

Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
https://www.onclive.com/view/pembrolizumab-cabozantinib-combo-provides-benefit-in-mrcc

Jul 1st, 2021 - The combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx) induced a response in more than half of patients with metastatic renal cell carcinoma (mRCC) at the recommended phase 2 dose (RP2D) with a manageable safety profile, meeting ...

Camidanlumab Tesirine Elicits Encouraging ORR in Heavily Pretreated Hodgkin Lymphoma
https://www.onclive.com/view/camidanlumab-tesirine-elicits-encouraging-orr-in-heavily-pretreated-hodgkin-lymphoma

Jun 22nd, 2021 - Camidanlumab tesirine (ADCT-301) was found to elicit an objective response rate (ORR) of 66.3% in patients with relapsed/refractory Hodgkin lymphoma, according to interim data from a phase 2 study (NCT04052997) presented during the 16th Internatio...

see more →